Dendritic Cell-Gp100-Mart-1 Antigen Vaccine
Melanoma (Skin)
Genzyme, a Sanofi CompanyvaccinePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
152 Active assets in the Melanoma (Skin) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha-Interferon MIPO Clinic | Phase 3 | BBB |
DACARBAZINE Linnaeus Therapeutics, Inc. | Phase 3 | BBB |
TIL City of Hope Medical Center | Phase 2 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II MIPO Clinic | Phase 3 | BBB |
Tyrosinase Peptide University of Southern California | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Dendritic Cell-Gp100-Mart-1 Antigen Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →